Maurice Cohen, MD
Gastroenterology · Salem, NHNPI 1851482277
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 30.8% of the total. Reporting peaked in 2023 at $600 and has fallen 80.7% since, to $116 in 2024.
Across 103 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$563
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$501
- Johnson & Johnson$140
- Merck$135
- Takeda Pharmaceuticals U.S.A., Inc.$124
- Pfizer$85
- plus $281 from 8 others
What the payments were for
- Consulting fees$161%
- Food & beverage$1,79098%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $563 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 30 | $501 |
| Johnson & Johnson | 7 | $140 |
| Merck | 7 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $124 |
| Pfizer | 4 | $85 |
| Gilead | 3 | $58 |
| Shire North American Group Inc | 2 | $48 |
| Canon Medical Systems USA, Inc. | 1 | $45 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Bristol Myers Squibb | 1 | $27 |
| Ironwood Pharmaceuticals, Inc | 1 | $24 |
| Redhill Biopharma Inc. | 1 | $20 |
| Intercept Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$1,828 in reported general payments places this provider in the 70th percentile of 91 gastroenterology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 11 | $74,039 |
| Mesalamine | 18 | $10,329 |
| Balsalazide Disodium | 13 | $3,806 |
| Omeprazole | 69 | $726 |
| Dicyclomine Hcl | 11 | $696 |
| Pantoprazole Sodium | 30 | $536 |
| Famotidine | 32 | $366 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Salem
- Raja RehmanSalem$3K
- Lee KaplanLebanon$1.2M
- Corey SiegelLebanon$602K
- Brian LacyLebanon$177K
- Leon McLeanDerry$171K
- Shelby SullivanLebanon$137K
- Michael WinterLebanon$58K
- Stuart GordonLebanon$42K
- Robert RubenSomersworth$36K
- Hillary TompkinsExeter$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.